Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WTO Decision On Access To COVID-19 Vaccines: A Waiver In Name Only?

Agreement Could Be Extended To Medicines And Diagnostics In Six Months

Executive Summary

R&D-based companies have denounced what they see as a dangerous and unjustified attack on intellectual property after the World Trade Organization’s ministerial conference finally adopted a decision on an IP waiver for COVID-19 vaccines. NGOs, by contrast, say the decision amounts to little more than a limited exception to existing rules on the compulsory licensing of medicines.

You may also be interested in...



Pfizer Adds Hundreds Of Drugs To Global Health Equity Initiative

Pfizer has added hundreds of off-patent products to the portfolio that it is offering on a not-for-profit basis to 45 lower-income countries under its global health equity initiative.

UK Industry ‘Struggling’ With Skill Gaps In AI, Robotics & Data Analytics

A new report says that pharma firms are finding it difficult to recruit staff with experience in emerging scientific technologies, particularly in areas such as regulatory and quality assurance. COVID-19, Brexit and competition for talent with other countries and industry sectors are cited as key factors.

Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages

The Canadian government says stakeholders are “poised for action” to improve the collective response to medical product shortages and has come up with some questions and possible answers as to how best to go about it.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel